Singapore, Sept. 25 -- The Health Sciences Authority received information related to the study titled 'A PHASE III, MULTICENTER, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF SUBCUTANEOUS INDUCTION THERAPY WITH AFIMKIBART IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS'. The following are the other relevant details related to the trial:
Therapeutic Area: Immunology
Trial Centre(s):
Changi General Hospital
Gastroenterology and Liver Specialist Clinic
Tan Tock Seng Hospital
Trial Status: NA
Principal Investigator(s):
Dr Dr Tan Chin Kimg
Dr Ling Khoon Lin
Dr Lin Huiyu
Published by HT Digital Content Services with permission from Health Daily Digest....